Anupam Rasayan India Ltd. · NSE:ANURAS
Anupam Rasayan India — Merger or Acquisition (May 2026)
9 slides from Anupam Rasayan India's merger presentation, May 23, 2026
Slide 1: Exchange filing cover letter - Investor Presentation Acquisition
ANUPAM RASAYAN INDIA LTD. R ARILSLDSTX20260523017 Date: May 23, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, ‘Exchange Plaza’, C-1, Block-G, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai-400001, India. Mumbai-400051, India. SCRIP CODE: 5432
Slide 2: Anupam Rasayan India Limited - Bliss GVS Pharma Acquisition
Anupam Rasayan India Limited Bliss GVS Pharma Acquisition May 2026
Slide 3: Safe Harbour
Safe Harbour Anupam Rasayan India Limited | ‹#› 2 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Anupam Rasayan India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invita
Slide 4: Brief Overview – Bliss GVS Pharma Limited
Brief Overview – Bliss GVS Pharma Limited Anupam Rasayan India Limited | ‹#› 3 Global Accreditations Incorporated in 1984. • 150+ • Manufactures branded formulations Brands across Anti-malarial, Anti-fungal, Anti- bacterial, Antibiotic, anti-inflammatory, Anti-infective, Anti-diabetic, Cardiovascula
Slide 5: Performance Trend: Bliss GVS Pharma
Performance Trend : Bliss GVS Pharma Anupam Rasayan India Limited | ‹#› 4 Revenue (Rs. Crore) EBITDA (Rs. crore) Rs 167 Crores 16% 20% 16% 18% 927 770 810 Cash & Cash Equivalents 752 164 151 127 117 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Zero Net Debt PAT (Rs. crore) 10% 11% 11% 14% 135 Rs. 139 Cro
Slide 6: Expansion, Integration & Opportunities
Expansion, Integration & Opportunities Anupam Rasayan India Limited | ‹#› 5 Synergies with Therapeutic Areas: Expansion into Cardiovascular, Expansion into CDMO Business: Forward Integration: Antidiabetic, Antibiotics, Analgesic & Expanding into regulated markets End-to-End Vertically integrated Ant
Slide 7: State-of-the-Art Manufacturing Facilities
State-of-the-Art Manufacturing Facilities Anupam Rasayan India Limited | ‹#› 6 Palghar Vevoor Ambernath Dosage Dosage Dosage ✓ Tablet ✓ Tablet ✓ Ointment ✓ Dry syrup ✓ Capsule ✓ Cream 4,822 mn units ✓ Sachet ✓ Suppository ✓ Sachet ✓ Ointment ✓ Gel Installed Capacity ✓ Cream and Gel Capacity - 758 mn
Slide 8: Transaction Details
Transaction Details Anupam Rasayan India Limited | ‹#› 7 Deal overview Transaction structure 43.3-48.2%+Open Offer to the public Global Investment Anupam Lender Management firm shareholders for controlling stake of Bliss GVS Pharma, an India-based pharmaceutical formulations company engaged in the d
Slide 9: Thank You
Company Details: Anupam Rasayan Ltd. CIN – L24231GJ2003PLC042988 Investor Relations Advisor : Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net Mobile No – 9619595686 / 9819494608 www.sgapl.
Anupam Rasayan India — Merger or Acquisition (May 2026) on 6ix